TLDR
-
Nanobiotix gains $71M boost to fuel NBTXR3’s clinical momentum and growth.
-
$71M royalty deal extends Nanobiotix’s cash runway into early 2028.
-
HCRx funding powers Nanobiotix’s late-stage cancer nanotherapy pipeline.
-
Nanobiotix secures key financing to strengthen oncology innovation push.
-
Financing milestone sets Nanobiotix on path to sustainable cancer care.
Nanobiotix S.A. (NASDAQ: NBTX) gained 2.5%, closing at $18.44 after securing a $71 million royalty-based financing deal.
The transaction with HealthCare Royalty (HCRx) aims to extend the company’s cash visibility into early 2028. The move strengthens its financial position and supports continued development of its oncology nanotherapeutics pipeline.
Strengthened Financial Position and Extended Cash Runway
Nanobiotix executed a financing agreement with HealthCare Royalty to receive up to $71 million in non-dilutive capital. The company will receive an upfront payment of $50 million and expects another $21 million one year later upon meeting conditions. This agreement provides flexibility to advance late-stage programs while maintaining shareholder value.
The funding ensures operational stability and supports research through critical clinical milestones in head and neck and lung cancer. It also establishes a financial base for self-sustainability as the company advances next-generation nanotherapeutic platforms. The agreement reflects Nanobiotix’s strategy to align capital resources with long-term growth goals.
Under the terms, repayment to HCRx will derive from a capped share of royalties and milestone revenues from JNJ-1900 (NBTXR3). The total repayment will not exceed approximately $124 million if completed by 2030 or $178 million if beyond that period. After repayment, HCRx will receive a reduced royalty share for up to 10 years following the first U.S. commercial sale.
Advancing JNJ-1900 (NBTXR3) Through Key Clinical Milestones
JNJ-1900, also known as NBTXR3, remains the centerpiece of Nanobiotix’s oncology portfolio. The therapy uses hafnium oxide nanoparticles activated by radiotherapy to destroy tumor cells and stimulate immune response. Its mechanism supports broad scalability across solid tumors and combination treatments, including immune checkpoint inhibitors.
The company is leading global clinical development through the NANORAY-312 Phase 3 trial in head and neck squamous cell carcinoma. The U.S. FDA has granted Fast Track designation for the program targeting patients ineligible for platinum-based chemotherapy. Additionally, ongoing studies explore its use across tumor types in collaboration with MD Anderson Cancer Center.
Nanobiotix continues its partnership with Janssen Pharmaceutica, a Johnson & Johnson company, to co-develop and commercialize JNJ-1900 globally. The firm expects milestone payments from this partnership as programs reach key development stages. These payments, together with the new financing, secure resources for the company’s near-term and long-term objectives.
Building a Platform for Sustainable Growth
Nanobiotix focuses on physics-based therapeutic innovations in oncology and other diseases. The company operates subsidiaries in Cambridge, Massachusetts, and maintains listings on Euronext Paris and Nasdaq. Its portfolio includes over 25 patents spanning oncology, bioavailability, and central nervous system applications.
The financing deal supports progress beyond existing trials and lays groundwork for future product platforms. By combining financial stability with technological advancement, Nanobiotix positions itself for sustainable expansion in the cancer therapy market. The strengthened balance sheet enhances its ability to pursue additional partnerships and development programs.
The transaction underscores Nanobiotix’s readiness to transition toward long-term self-sufficiency. With extended cash visibility and growing clinical momentum, the company strengthens its leadership in nanotherapeutics innovation. The funding marks a pivotal step toward realizing its mission of expanding treatment possibilities for patients worldwide.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
